Puma Biotechnology, Inc. (PBYI)

Oncology Corporate Profile

Stock Performance

38.9000
0.0000

HQ Location

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024

Company Description

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation.

Website: http://www.pumabiotechnology.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
neratinib / PB272 (+ xeloda)tyrosine kinase inhibitorBreast cancerIII
neratinib / PB272tyrosine kinase inhibitorBreast cancerIII
neratinib / PB272 (+ pacitaxel)tyrosine kinase inhibitorBreast cancerII
neratinib / PB272 (+ torisel)tyrosine kinase inhibitorBreast cancerII
neratinib / PB272tyrosine kinase inhibitorVarious cancer typesII

View additional information on product candidates here »

Pipeline image

Source


http://www.pumabiotechnology.com/

Recent News Headlines

Puma Biotechnology to Present at Cowen’s Health Care Conference

3/2/2017 09:02 pm

[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:20 p.m.

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017

3/1/2017 11:00 pm

[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research Annual Meeting 2017.

Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272

3/1/2017 09:04 pm

[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that based on its recent meeting with the Rapporteur, Co-Rapporteur and review team members, as well as the European Medicines Agency , the Company plans to modify the summary of product characteristics , sometimes referred to as the European product label, in its Marketing Authorisation Application to restrict the intended population ...

Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results

3/1/2017 09:02 pm

[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2016.

Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference

2/14/2017 09:01 pm

[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 2:05 p.m.

Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference

2/8/2017 09:01 pm

[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:00 a.m.